I agree with you Bear.  There is too much science in this company...data and molecules that a big pharma would be willing to buy, for much more than the $100 to $150 million market cap implied right now.  I think the company needs to seriously explore selling itself to a major Big Pharma.

They are the first in class in CVD. Other molecules that may be tested down the line.  I am still in shock about how Apabetalone did not work...I mean why would it not work?  All the bio markers were supposed to be going the right way.

The company always suffered from capital shortage.  So maybe the eventual value is back at $2 to 3 for a take out of the company in the short run. 

Longer run, I think they will struggle to raise capital.  This was meant to be a Hail Mary pass...and we are now out of bullets.